PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with type 2 diabetes managed by diet and exercise alone. Two estimands addressed two efficacy-related questions: a treatment policy estimand (regardless of trial product discontinuation or rescue medication use) and a trial product estimand (on trial product without rescue medication use) in all randomized patients. RESEARCH DESIGN AND METHODS: This was a 26-week, phase 3a, randomized, double-blind, placebo-controlled, parallel-group trial conducted in 93 sites in nine countries. Adults with type 2 diabetes insufficiently controlled with diet and exercise were randomized (1:1:1:1) to once-daily oral semaglutide 3 mg, 7 mg, 14 mg, or placebo. The primary end point was change from baseline to week 26 in HbA1c. The confirmatory secondary end point was change from baseline to week 26 in body weight. RESULTS: In the 703 patients randomized (mean age 55 years, 50.8% male, and mean baseline HbA1c 8.0% [64 mmol/mol]), oral semaglutide reduced HbA1c (placebo-adjusted treatment differences at week 26: treatment policy estimand, −0.6% [3 mg], −0.9% [7 mg], and −1.1% [14 mg]; trial product estimand, −0.7% [3 mg], −1.2% [7 mg], and −1.4% [14 mg]; P < 0.001 for all) and body weight (treatment policy, −0.1 kg [3 mg], −0.9 kg [7 mg], and −2.3 kg [14 mg, P < 0.001]; trial product, −0.2 kg [3 mg], −1.0 kg [7 mg, P = 0.01], and −2.6 kg [14 mg, P < 0.001]). Mild-to-moderate transient gastrointestinal events were the most common adverse events with oral semaglutide. Trial product discontinuations occurred in 2.3–7.4% with oral semaglutide and 2.2% with placebo. CONCLUSIONS: In patients with type 2 diabetes, oral semaglutide monotherapy demonstrated superior and clinically relevant improvements in HbA1c (all doses) and body weight loss (14 mg dose) versus placebo, with a safety profile consistent with other GLP-1 receptor agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapies shown to positively affect albuminuria and declining eGFR include ACE inhibitors, ARBs, SGLT2is, GLP-1 RAs, and the nonsteroidal mineralocorticoid antagonist finerenone.197,209,239,242,393,423–435”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin and canagliflozin demonstrated reduction in MACE in CVOTs; empagliflozin also demonstrated decreased CV death and all-cause mortality.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have shown a decrease in hospitalization for HF in their CVOTs.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Dapagliflozin based on the DAPA-CKD RCT424 has received an FDA indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization for HF in adults with CKD at risk of progression.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
In the citing paper
“Multiple studies have shown renal and CV benefits of SGLT2is239,424–426,444,1052–1054”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [424]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationStatistical Analysis With Missing Data
Ghosh, S. (1988) · Technometrics · doi:10.1080/00401706.1988.10488446 · Cited by 4,576
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
International Conference on Harmonisation
Guy, R. C. (2014) · Encyclopedia of Toxicology · doi:10.1016/b978-0-12-386454-3.00861-7 · Cited by 1,478
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“†Severe hypoglycemia was defined according to the American Diabetes Association classification (16) (requiring assistance of another person to actively administer carbohydrateor glucagonor takeother correctiveactions).”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 2×
“The safety profile of oral semaglutide was generally consistent with that reported for subcutaneous semaglutide (19)”
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Cited by
Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080
Self-citationAdvances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558
Marx, N., Husain, M., Lehrke, M., Verma, S., & Sattar, N. (2022) · Circulation · doi:10.1161/circulationaha.122.059595 · Cited by 483
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302392 · Cited by 478
Self-citationRodbard, H. W., Rosenstock, J., Canani, L. H., Deerochanawong, C., Gumprecht, J., Lindberg, S. Ø., Lingvay, I., Søndergaard, A. L., Treppendahl, M. B., Montanya, E., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0883 · Cited by 463
Self-citationSmits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001952 · Cited by 240
Obesity and cardiovascular disease: An ESC clinical consensus statement
Koskinas, K. C., Van Craenenbroeck, E. M., Antoniades, C., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae508 · Cited by 313
Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, et al. (2019) · Diabetes Care · doi:10.2337/dc19-0898 · Cited by 300
Self-citationSystemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S., & Mrsny, R. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.007 · Cited by 253
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
Yamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30075-9 · Cited by 228
Self-citationYabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30074-7 · Cited by 210
Self-citationHusain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209
Self-citationNørgaard, C. H., Friedrich, S., Hansen, C. T., Gerds, T., Ballard, C., Møller, D. V., Knudsen, L. B., Kvist, K., Zinman, B., Holm, E., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12268 · Cited by 206
Kloock, S., Ziegler, C. G., & Dischinger, U. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108549 · Cited by 197
Sethi, S., Wakeham, D. E., Ketter, T. A., Hooshmand, F., Bjornstad, J., Richards, B. J., Westman, E. C., Krauss, R. M., & Saslow, L. R. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115866 · Cited by 179
“…to 1000 mg twice a day) achieved a reduction in HbA1c of 0.9% (Erem et al., 2014), thiazolidinediones (rosiglitazone or pioglitazone) achieved 0.8 – 1.1% A1c reduction (Yoon et al., 2011), and on average GLP–1 agonists achieved a reduction of 1.1 – 1.3% (Aroda et al., 2019; Garber et al., 2009).”
BackgroundInfluentialActivation of the GLP-1 receptor by a non-peptidic agonist
Zhao, P., Liang, Y.-L., Belousoff, M. J., Deganutti, G., Fletcher, M. M., Willard, F. S., Bell, M. G., Christe, M. E., Sloop, K. W., Inoue, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1902-z · Cited by 164
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-014919 · Cited by 158
Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials
Overgaard, R. V., Navarria, A., Ingwersen, S. H., Bækdal, T. A., & Kildemoes, R. J. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01025-x · Cited by 158
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist
Bucheit, J. D., Pamulapati, L. G., Carter, N., Malloy, K., Dixon, D. L., & Sisson, E. M. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0185 · Cited by 156
“22 This review focuses on the peer-reviewed data for the PIONEER program using the primary statistical approach or the trial policy es-timand, since it is the traditional standard for clinical trials.”
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 150
“of different background medications [47–50, 52, 53, 55], including diet and exercise [46, 54].”
BackgroundInfluentialGibbons, C., Blundell, J., Tetens Hoff, S., Dahl, K., Bauer, R., & Bækdal, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14255 · Cited by 149
Efficacy of semaglutide in a subcutaneous and an oral formulation
Meier, J. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645617 · Cited by 146
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A. D., Koliaki, C. C., & Mantzoros, C. S. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 149
Obesity and cardiovascular disease: an ESC clinical consensus statement
Koskinas, K. C., Craenenbroeck, E. M. V., Antoniades, C. A., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae279 · Cited by 146
Luna-Marco, C., de Marañon, A. M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernández-Reyes, M., Apostolova, N., Vila, J. M., Solá, E., Morillas, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102849 · Cited by 141
Kirwan, J. P., Courcoulas, A. P., Cummings, D. E., Goldfine, A. B., Kashyap, S. R., Simonson, D. C., Arterburn, D. E., GOURASH, W. F., Vernon, A. H., Jakicic, J. M., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2441 · Cited by 136
Aroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135
“PIONEER 1 compared oral semaglutide with placebo [76], while PIONEER 2–4 compared oral semaglutide with the SGLT2i empagliflozin (25 mg once daily), the DPP-4 inhibitor sitagliptin (100 mg once daily), and the subcutaneous GLP-1RA liraglutide (1.”
BackgroundMethodInfluentialSelf-citationThethi, T. K., Pratley, R., & Meier, J. J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14054 · Cited by 134
“8 mg (n = 284) 211 (74) 22 (8) 22 (8) 26 (9) 17 (6) 7 (2) Placebo (n = 142) 95 (67) 7 (5) 15 (11) 5 (4) 3 (2) 3 (2) PIONEER 7 (N = 504) Oral semaglutide (flexible 3, 7 or 14 mg) (n = 253) 197 (78) 16 (6) 24 (9) 22 (9) 14 (6) 14 (6) Sitagliptin 100 mg (n = 250) 172 (69) 18 (7) 24 (10) 8 (3) 2 (1) 14 (6) PIONEER 9 (N =…”
Sarma, S., & Palcu, P. (2022) · Obesity · doi:10.1002/oby.23563 · Cited by 133
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Self-citationSherwin, M., Hamburger, J., Katz, D., & DeMaria, S. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02549-5 · Cited by 132
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
“, 2019 (57) NCT02906930 31 Semaglutide Placebo 2/525 0/178 55.”
Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Self-citationMin, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 129
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 126
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Formulation strategies to improve the efficacy of intestinal permeation enhancers,
Maher, S., & Brayden, D. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113925 · Cited by 113
Muzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 123
“07) compared with placebo.(145) Several large as well did some smaller dedicated GLP-1 RA clinical trials collected lipid data as secondary outcomes proving favorable effects on lipoprotein metabolism, with modest LDL-C, total cholesterol (TC), and fasting TG lowering.”
BackgroundResultChiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Overgaard, R. V., HERTZ, C. L., Ingwersen, S. H., Navarria, A., & Drucker, D. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100387 · Cited by 112
Self-citationDo GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis
Piccoli, G. F., Mesquita, L. A., Stein, C., Aziz, M. M., Zoldan, M., Degobi, N. A. H., Spiazzi, B. F., Junior, G. L. L., Colpani, V., & Gerchman, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa891 · Cited by 98
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis
Avgerinos, I., Michailidis, T., Liakos, A., Karagiannis, T., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13899 · Cited by 102
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
Self-citationGLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
Brunton, S., & Wysham, C. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798099 · Cited by 95
Richards, P., Thornberry, N. A., & Pinto, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101175 · Cited by 92
Koliaki, C. C., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00396-9 · Cited by 92
Dahl, K., Brooks, A., Almazedi, F., Hoff, S. T., Boschini, C., & Bækdal, T. A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14373 · Cited by 87
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Oral semaglutide in type 2 diabetes
Anderson, S. L., Beutel, T. R., & Trujillo, J. M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107520 · Cited by 83
Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals
Kim, J. C., Park, E. J., & Na, D. H. (2022) · Pharmaceuticals · doi:10.3390/ph15121585 · Cited by 83
Kalra, S., & Sahay, R. K. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00894-y · Cited by 89
Cernea, S., Dima, L., Correll, C. U., & Manu, P. (2020) · Drugs · doi:10.1007/s40265-020-01393-x · Cited by 83
Wang, F., Mao, Y., Wang, H., Liu, Y., & Huang, P. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01110-w · Cited by 75
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 78
“Moving to the second program, the Pioneer studies, which sought to determine the effectiveness and safety of oral semaglutide [187].”
BackgroundInfluentialVolpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Triggiani, V., Sabbà, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240263 · Cited by 73
“The result agrees with data from the main PIONEER studies (10, 14), with a response rate of 50%, which should be considered a satisfactory endpoint in this population.”
Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?
Mirzadeh, Z., Faber, C. L., & Schwartz, M. W. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-010446 · Cited by 74
Aroda, V. R., Saugstrup, T., Buse, J. B., Donsmark, M., Zacho, J., & Davies, M. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13804 · Cited by 71
“An unstructured covariance matrix for endpoint measurements within the same patient was employed.(9)”
InfluentialSelf-citationHorn, D. B., Ryan, D. H., Kis, S. G., Alves, B., Mu, Y., Kim, S. G., Aberle, J., Bain, S. C., Allen, S., Sarker, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02165-8 · Cited by 70
Bonora, E., Frias, J. P., Tinahones, F. J., Van, J., Malik, R. E., Yu, Z., Mody, R., Bethel, A., Kwan, A. Y. M., & Cox, D. A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14465 · Cited by 67
Vosoughi, K., Salman Roghani, R., & Camilleri, M. (2022) · Obesity Medicine · doi:10.1016/j.obmed.2022.100456 · Cited by 65
Aroda, V. R., Erhan, U., Jelnes, P., Meier, J. J., Abildlund, M. T., Pratley, R. E., Vilsbøll, T., & Husain, M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14990 · Cited by 71
“Blood pressure was modestly decreased in patients treated with subcutaneous/oral semaglutide (systolic: –4/–3; diastolic: –1/–1 mmHg; Table S12).”
BackgroundMethodSelf-citationPratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15150 · Cited by 60
“3 kg after 26 weeks of treatment.(18) Higher doses of oral semaglutide are under development.”
BackgroundFeier, C., Vonica, R., Faur, A., Streinu, D., & Muntean, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084346 · Cited by 60
“For instance, studies such as those by Aroda VR et al. [33] and Zinman B et al. [35] were omitted because they did not focus on or mention thyroid cancer incidence, despite discussing semaglutide’s effects in diabetes management.”
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
Aroda, V. R., Faurby, M. D., Lophaven, S., Noone, J. M., Wolden, M. L., & Lingvay, I. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14453 · Cited by 59
Self-citationSolis‐Herrera, C., Kane, M. P., & Triplitt, C. L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0118 · Cited by 59
Sachinidis, A. G., Nikolić, D., Stoian, A. P., Παπάνας, Ν., Tarar, O. H., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 61
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58
Liu, B. D. X., Udemba, S. C., Liang, K., Tarabichi, Y., Hill, H., Fass, R., & Song, G. (2023) · Gut · doi:10.1136/gutjnl-2023-329651 · Cited by 61
Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials
Caruso, I., Cignarelli, A., & Giorgino, F. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.07.004 · Cited by 58
Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis
Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57
Influence of Bile Composition on Membrane Incorporation of Transient Permeability Enhancers
Hossain, S., Joyce, P. M., Parrow, A., Jõemetsa, S., Höök, F., Larsson, P., & Bergström, C. A. S. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00668 · Cited by 57
Bækdal, T. A., Breitschaft, A., Donsmark, M., Maarbjerg, S., Søndergaard, F. L., & Borregaard, J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01078-y · Cited by 58
Li, A., Su, X., Hu, S., & Wang, Y. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110605 · Cited by 65
Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01106-4 · Cited by 56
Eliminating Ambiguous Treatment Effects Using Estimands
Kahan, B. C., Cro, S., Li, F., & Harhay, M. O. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad036 · Cited by 59
Allan, K. C., Joo, J. H., Kim, S., Shaia, J., Kaelber, D. C., Singh, R., Talcott, K. E., & Rachitskaya, A. V. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2025.01.016 · Cited by 54
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
Rasmussen, M. F. (2020) · Diabetology International · doi:10.1007/s13340-019-00423-8 · Cited by 57
Crawford, A. L., & Laiteerapong, N. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202406180 · Cited by 54
Yeh, T., Tsai, M.-C., Tsai, W.-H., Tu, Y., & Chien, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278685 · Cited by 52
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Salvador, R., Moutinho, C. M. S. G., Sousa, C., Vinha, A. F., Carvalho, M. C., & Matos, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18030399 · Cited by 55
“This group of PIONEER studies was important in demonstrating that oral SMG is effective for controlling glycemia and reducing weight in patients with DM2 [68,76,78–83] and as a non-inferior option compared to injectables for glycemic control [84–86].”
Ko, A., Chang, Y.-C., Bahar, F., Wang, T. H., Xanthavanij, N., Yu, C.-C., Hsieh, R. J.-L., See, X. Y., Lo, S., Song, J., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-02237 · Cited by 55
Perspectives on Virtual (Remote) Clinical Trials as the “New Normal” to Accelerate Drug Development
Alemayehu, D., Hemmings, R., Natarajan, K., & Roychoudhury, S. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2248 · Cited by 50
Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease
Triggle, C. R., Ding, H., Marei, I., Anderson, T. J., & Hollenberg, M. D. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0677 · Cited by 49
Banerjee, M., Pal, R., Mukhopadhyay, S., & Nair, K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad076 · Cited by 49
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Choe, H. J., & Cho, Y. M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.102 · Cited by 50
“A series of 10 phase 3 multicenter, randomized clinical studies as part of the Peptide InnOvatioN for Early diabetes tReatment (PIONEER) program were conducted to compare the efficacy and safety of oral semaglutide with either placebo or active comparators [21-31].”
BackgroundMetabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 52
Niazi, S., Gnesin, F., Thein, A.-S., Andreasen, J. R., Horwitz, A., Mouhammad, Z. A., Jawad, B. N., Niazi, Z., Pourhadi, N., Zareini, B., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.03.004 · Cited by 47
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 47
Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management
Chun, J. H., & Butts, A. (2020) · JAAPA · doi:10.1097/01.jaa.0000669456.13763.bd · Cited by 52
Tipa, R. O., Bălan, D.-G., Géorgescu, M., Ignat, L. A., Văcăroiu, I. A., Georgescu, D. E., Răducu, L., Mihai, D. A., Chiperi, L. V., & Balcangiu‐Stroescu, A.-E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094972 · Cited by 49
“Also, the Phase 3 clinical trial EVOKE aims to assess the safety and efficacy of orally administered semaglutide in the early stages of Alzheimer’s Disease [53–55].”
BackgroundBækdal, T. A., Donsmark, M., Hartoft‐Nielsen, M., Søndergaard, F. L., & Connor, A. L. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.938 · Cited by 44
“The majority of subjects (22) were White, whereas 3 were Asian, and 1 was Black/African American.”
BackgroundYin, D., Ding, L., Zhou, H., Qiu, M., & Duan, X.-Y. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej21-0129 · Cited by 43
Metadata
- Authors
- Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., PIONEER 1 Investigators, Belkacem, K., Chiali, N., Bourezane, S., Guermaz, R., Popivanov, P., Lefterov, I., Tankova, T., Penchev, I., Koskova, M., Hudcova, M., Vesela, A., Rancova, A., Haluzik, M., Kiyosue, A., Matsuoka, O., Inoue, S., Terauchi, Y., Fukushima, Y., Ide, Y., Violante Ortiz, R. M., Morales Villegas, E., Golovach, A., Alpenidze, D., Frolova, E., Zhdanova, E., Ruyatkina, L., Ershova, O., Samoilova, Y., Zyangirova, S., Lalic, K., Lalic, N., Beljic Zivkovic, T., Ataoglu, E., Bakiner, O., Dayan, A., Sargin, M., Mert, M., Adas, M., Tabak, O., Altuntas, Y., Murray, A., Iranmanesh, A., Schlau, A., Wieskopf, B., Snyder, B., Griffin, C., Fogarty, C., Lovell, C., Allison, D., Fitz-Patrick, D., Grant, D., Klonoff, D., Williams, D., Armas, E., Palace, E., Ruoff, G., Martinez, G., Perez, G., Bays, H., Tatu, H., Maynard, J., Cedeno, J.-E., Aroda, V., Park, J., Sutton, J., Pouzar, J., Bertsch, J., Condit, J., Serje, J., Cabaccan, J., Risser, J., Frias, J., Rosenstock, J., Sivalingam, K., Maw, K., Hanson, L., Billings, L., Connery, L., Juarez, M., Lillestol, M., Fraser, N., Beckett, P., Wade, R., Gaona, R., Jackson, R., DeLuca, R., Alpizar, S., Herring, S., Stringam, S., Bauer, S., Gangi, S., Sligh, T., Jarrett, W., & Fitzgibbons, W.
- Affiliations
- Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
- Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- Cardiometabolic Research Center, Aguascalientes, Mexico
- Novo Nordisk (Denmark) (DK)
- Institute for Clinical and Experimental Medicine and Institute for Endocrinology, Prague, Czech Republic
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-11
- Volume
- 42
- Issue
- 9
- Pages
- 1724-1732
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2951522032
- Cited by
- 493
- References
- 23
- Citations by year
- 2026: 60 · 2025: 107 · 2024: 91 · 2023: 56 · 2022: 53 · 2021: 55 · 2020: 57 · 2019: 13
- FWCI
- 36.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- oral semaglutide, type 2 diabetes, GLP-1 receptor agonists, monotherapy, HbA1c, glycemic control, weight loss, treatment policy estimand, gastrointestinal adverse effects, drug discontinuation, dose comparison, treatment efficacy and safety
- MeSH terms
- Semaglutide, Administration, Oral, Adult, Diabetes Mellitus, Type 2, Diet, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Exercise
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.